Commentary on: "study of the pharmacokinetic changes of tramadol in diabetic rats" is the handicapped renal pathway in DMIS contributing for the increased bioavailability of tramadol?
作者信息
Srinivas Nuggehally R
机构信息
Suramus Biopharm, J,P, Nagar, I Phase, Bangalore, 560078, India.
出版信息
Daru. 2013 Mar 15;21(1):23. doi: 10.1186/2008-2231-21-23.
Abstract
摘要
相似文献
1
Commentary on: "study of the pharmacokinetic changes of tramadol in diabetic rats" is the handicapped renal pathway in DMIS contributing for the increased bioavailability of tramadol?
Daru. 2013 Mar 15;21(1):23. doi: 10.1186/2008-2231-21-23.
2
Study of the pharmacokinetic changes of Tramadol in diabetic rats.
Daru. 2013 Mar 7;21(1):17. doi: 10.1186/2008-2231-21-17.
3
Bioavailability of tramadol hydrochloride after administration via different routes in rats.
Biopharm Drug Dispos. 2014 Dec;35(9):525-31. doi: 10.1002/bdd.1916. Epub 2014 Sep 27.
4
Comparative pharmacokinetic study of paclitaxel and docetaxel in streptozotocin-induced diabetic rats.
Biopharm Drug Dispos. 2012 Nov;33(8):474-86. doi: 10.1002/bdd.1814. Epub 2012 Sep 14.
5
Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
Arzneimittelforschung. 1998 May;48(5):436-45.
6
Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 4th communication: drops (without ethanol).
Arzneimittelforschung. 2000 Feb;50(2):99-108. doi: 10.1055/s-0031-1300173.
7
Pharmacokinetics of tramadol in rat plasma and cerebrospinal fluid after intranasal administration.
J Pharm Pharmacol. 2008 Sep;60(9):1149-54. doi: 10.1211/jpp.60.9.0005.
8
Plasma glucose-lowering effect of tramadol in streptozotocin-induced diabetic rats.
Diabetes. 2001 Dec;50(12):2815-21. doi: 10.2337/diabetes.50.12.2815.
9
Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories.
Arzneimittelforschung. 1998 Sep;48(9):889-99.
10
Pharmacokinetic properties of tramadol sustained release capsules. 2nd communication: investigation of relative bioavailability and food interaction.
Arzneimittelforschung. 1999 Jul;49(7):588-93. doi: 10.1055/s-0031-1300467.
本文引用的文献
1
Study of the pharmacokinetic changes of Tramadol in diabetic rats.
Daru. 2013 Mar 7;21(1):17. doi: 10.1186/2008-2231-21-17.
2
Diabetic painful neuropathy: current and future treatment options.
Drugs. 2007;67(4):569-85. doi: 10.2165/00003495-200767040-00006.
3
Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy.
Curr Med Res Opin. 2007 Jan;23(1):147-61. doi: 10.1185/030079906X162674.
4
Metabolism of the analgesic drug ULTRAM (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites.
Xenobiotica. 2002 May;32(5):411-25. doi: 10.1080/00498250110113230.
5
Plasma glucose-lowering effect of tramadol in streptozotocin-induced diabetic rats.
Diabetes. 2001 Dec;50(12):2815-21. doi: 10.2337/diabetes.50.12.2815.
6
Metabolism of the analgesic drug, tramadol hydrochloride, in rat and dog.
Xenobiotica. 2001 Jul;31(7):423-41. doi: 10.1080/00498250110057378.
7
Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats.
Res Commun Mol Pathol Pharmacol. 1996 Sep;93(3):343-52.
8
[Biotransformation of tramadol in man and animal (author's transl)].
Arzneimittelforschung. 1981;31(11):1932-43.
9
Effect of diabetes on disposition and renal handling of cefazolin in rats.
Drug Metab Dispos. 1990 Sep-Oct;18(5):565-70.
Zotero 插件